TRACON Pharmaceuticals Management

Management criteria checks 3/4

TRACON Pharmaceuticals' CEO is Charles Theuer, appointed in Jul 2006, has a tenure of 17.75 years. total yearly compensation is $1.08M, comprised of 58.6% salary and 41.4% bonuses, including company stock and options. directly owns 0.89% of the company’s shares, worth $36.37K. The average tenure of the management team and the board of directors is 4.6 years and 9.3 years respectively.

Key information

Charles Theuer

Chief executive officer

US$1.1m

Total compensation

CEO salary percentage	58.6%
CEO tenure	17.8yrs
CEO ownership	0.9%
Management average tenure	4.6yrs
Board average tenure	9.3yrs

Recent management updates

Recent updates

Tracon Pharmaceuticals announces $35M non-dilutive debt facility

Sep 06

Tracon Pharma gets FDA nod to start phase 1/2 trial of triplet combo to treat sarcoma

Aug 29

Dosing underway for TRACON Pharma's envafolimab in mid-stage soft tissue cancer study

Dec 10

Tracon Pharma files China application for envafolimab in solid tumors

Nov 16

CEO Compensation Analysis

How has Charles Theuer's remuneration changed compared to TRACON Pharmaceuticals's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$1m	US$632k	-US$4m
Sep 30 2023	n/a	n/a	-US$11m
Jun 30 2023	n/a	n/a	-US$28m
Mar 31 2023	n/a	n/a	-US$28m
Dec 31 2022	US$1m	US$608k	-US$29m
Sep 30 2022	n/a	n/a	-US$30m
Jun 30 2022	n/a	n/a	-US$30m
Mar 31 2022	n/a	n/a	-US$33m
Dec 31 2021	US$2m	US$585k	-US$29m
Sep 30 2021	n/a	n/a	-US$25m
Jun 30 2021	n/a	n/a	-US$22m
Mar 31 2021	n/a	n/a	-US$18m
Dec 31 2020	US$1m	US$568k	-US$17m
Sep 30 2020	n/a	n/a	-US$16m
Jun 30 2020	n/a	n/a	-US$18m
Mar 31 2020	n/a	n/a	-US$19m
Dec 31 2019	US$1m	US$553k	-US$23m
Sep 30 2019	n/a	n/a	-US$26m
Jun 30 2019	n/a	n/a	-US$30m
Mar 31 2019	n/a	n/a	-US$34m
Dec 31 2018	US$1m	US$542k	-US$35m
Sep 30 2018	n/a	n/a	-US$34m
Jun 30 2018	n/a	n/a	-US$24m
Mar 31 2018	n/a	n/a	-US$20m
Dec 31 2017	US$1m	US$532k	-US$19m

Compensation vs Market: Charles's total compensation ($USD1.08M) is above average for companies of similar size in the US market ($USD668.06K).

Compensation vs Earnings: Charles's compensation has been consistent with company performance over the past year.

CEO

Charles Theuer (59 yo)

17.8yrs

Tenure

US$1,078,633

Compensation

Dr. Charles P. Theuer, M.D. & Ph D., has been the President and Chief Executive Officer of Tracon Pharmaceuticals, Inc. since July 2006 and has been its Director of Tracon Pharmaceuticals, Inc. since June...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Charles Theuer	Chairman	17.8yrs	US$1.08m	0.89% $ 36.4k
Scott Brown	Chief Financial Officer	5.3yrs	US$590.49k	0.055% $ 2.2k
James Freddo	Chief Medical Officer	3.9yrs	no data	no data
Ya Huang	Executive Director of Statistical Programming	2.8yrs	no data	no data

4.6yrs

Average Tenure

59yo

Average Age

Experienced Management: TCON's management team is considered experienced (4.6 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Charles Theuer	Chairman	17.8yrs	US$1.08m	0.89% $ 36.4k
Stephen Worland	Independent Director	9.2yrs	US$75.65k	0.0017% $ 68.0
William LaRue	Independent Director	9.8yrs	US$84.40k	0.017% $ 694.4
Martin Mattingly	Independent Director	9.3yrs	US$78.15k	0.0017% $ 68.0
Saundra Pelletier	Independent Director	4.1yrs	US$79.40k	0.026% $ 1.1k
James Twiford	Independent Director	15.6yrs	US$69.40k	0.0017% $ 68.0
Stanton Gerson	Member of the Scientific Advisory Board	no data	no data	no data
Carol Lam	Independent Director	2.5yrs	US$69.40k	0% $ 0
Lisa Johnson-Pratt	Independent Director	3.1yrs	US$68.15k	0% $ 0

9.3yrs

Average Tenure

64yo

Average Age

Experienced Board: TCON's board of directors are considered experienced (9.3 years average tenure).

TRACON Pharmaceuticals Management

Management criteria checks 3/4

Key information

Recent management updates

Insufficient new directors

TRACON Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2022

TRACON Pharmaceuticals, Inc. Announces Appointment of Lisa Johnson-Pratt to its Board of Directors

Tracon Pharmaceuticals, Inc. Announces Executive Changes

Recent updates

TRACON Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

TRACON Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

TRACON Pharmaceuticals Provides Update on Ongoing ENVASARC Phase 2 Pivotal Trial Following Independent Data Monitoring Committee Recommendation to Continue the Trial as Planned

Insufficient new directors

New major risk - Share price stability

New major risk - Shareholder dilution

TRACON Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 05, 2024

TRACON Pharmaceuticals, Inc. Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial

Consensus EPS estimates upgraded to US$0.45 loss

TRACON Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 09, 2023

New major risk - Revenue and earnings growth

New major risk - Share price stability

TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned

New major risk - Financial position

Consensus revenue estimates increase by 50%

TRACON Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 14, 2023

TRACON Pharmaceuticals Announces Positive Results Based on Ongoing Double-Digit Objective Response Rate for Single Agent Envafolimab in the ENVASARC Phase 2 Pivotal Trial

TRACON Pharmaceuticals Receives Notice from Nasdaq Regarding Non-Compliance with the Market Value Rule and Minimum Bid Price Requirement

Consensus revenue estimates increase by 100%

Price target decreased by 21% to US$7.33

TRACON Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 10, 2023

Price target decreased by 12% to US$9.33

No longer forecast to breakeven

TRACON Pharmaceuticals Receives A Letter from Nasdaq Regarding Market Value Rule

TRACON Pharmaceuticals Announces Positive Results Based on Double-Digit Objective Response Rate in Each Cohort from the Ongoing ENVASARC Phase 2 Pivotal Trial

TRACON Pharmaceuticals, Inc Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma

Price target decreased to US$10.20

TRACON Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

TRACON Pharmaceuticals, Inc. Announces Results of Independent Data Monitoring Committee Review of 12 Week Safety Data from Envasarc Phase 2 Pivotal Trial

TRACON Pharmaceuticals Announces Fast Track Designation by the Food and Drug Administration for Envafolimab for the Treatment of the Soft Tissue Sarcoma Subtypes of UPS and MFS

Tracon Pharmaceuticals announces $35M non-dilutive debt facility

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. and TRACON Pharmaceuticals, Inc. Announce U.S. Food and Drug Administration Approval of Investigational New Drug

Tracon Pharma gets FDA nod to start phase 1/2 trial of triplet combo to treat sarcoma

Consensus forecasts updated

TRACON Pharmaceuticals, Inc. Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial

Tracon GAAP EPS of -$0.31 beats by $0.05, revenue of $0M

TRACON Pharmaceuticals, Inc. Submits IND Application for CTLA-4 Antibody YH001 for the Treatment of Front-Line Sarcoma Patients in Combination with Envafolimab

TRACON Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 10, 2022

TRACON Pharmaceuticals Announces Dosing of 36Th Patient in Envasarc Pivotal Trial Triggering Initial Idmc Efficacy Review Expected in the Fourth Quarter

Consensus revenue estimates increase by 99%

TRACON Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 11, 2022

TRACON Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2022

Forecast to breakeven in 2024

TRACON Pharmaceuticals Announces Amended ENVASARC Protocol Approved and Open at all 30 Clinical Sites in the U.S. and U.K

No longer forecast to breakeven

No longer forecast to breakeven

TRACON Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 15, 2022

TRACON Pharmaceuticals Announces Initiation of Randomized Phase 2 Trial of TRC102 in Lung Cancer Sponsored by the National Cancer Institute

TRACON Pharmaceuticals Announces Positive Results from the Independent Data Monitoring Committee Review of Interim Safety and Efficacy Data from the Ongoing ENVASARC Pivotal Trial

TRACON Pharmaceuticals, Inc. Reports Regulatory Approval of Envafolimab in China

TRACON Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $15.000002 million.

TRACON Pharmaceuticals Presents Data from a Phase 1 Study of Uliledlimab (TJ004309) and Tecentriq® (Atezolizumab) at the American Society of Clinical Oncology Virtual Annual Meeting

TRACON Pharmaceuticals Announces Results of Independent Data Monitoring Committee Review of Safety Data from ENVASARC Pivotal Trial

TRACON Pharmaceuticals, Inc. Announces Appointment of Lisa Johnson-Pratt to its Board of Directors

TRACON Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $8.805977 million.

TRACON Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Tracon Pharmaceuticals, Inc. Announces Executive Changes

TRACON Pharmaceuticals announces $5M registered direct offering

TRACON Pharma launches $8.8M direct offering

TRACON Pharmaceuticals, Inc. Announces Dosing of First Patient in ENVASARC Pivotal Trial

Dosing underway for TRACON Pharma's envafolimab in mid-stage soft tissue cancer study

TRACON Pharmaceuticals, Inc. Announces Publication in Cancer Cell of Clinical Data That Provides Molecular Insight into the Mechanism of Action of Trc102 and Patient Populations Most Likely to Respond to Treatment

TRACON Pharmaceuticals Announces Submission for Approval of Envafolimab (KN035) with the NMPA in China by its Corporate Partners Alphamab Oncology and 3D Medicines

Tracon Pharma files China application for envafolimab in solid tumors

TRACON Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 10, 2020

Tracon Pharmaceuticals Highlights Updated Envafolimab Clinical Results in MSI-H/dMMR Colorectal Cancer

TRACON Pharmaceuticals, Inc. announced that it expects to receive $4.999998 million in funding from Opaleye Management Inc.

CEO Compensation Analysis

CEO

Tenure

Compensation